FINANCE/FUNDING ARTICLES

  • IP Due Diligence: 5 Questions You Must Ask In Corporate Transactions
    IP Due Diligence: 5 Questions You Must Ask In Corporate Transactions

    IP due diligence standards need to be continuously updated to stay current, especially, as biopharma companies increasingly pursue high-stakes, IP-intensive deals in which an overlooked IP issue can undermine the entire value of such a transaction. The following are the five questions you must ask in corporate transactions regarding IP due diligence.

  • Timeline And Developmental Activities When Resources Are Limited
    Timeline And Developmental Activities When Resources Are Limited

    It is increasingly rare that early-stage compounds or platform technologies are acquired without demonstration of clinical effect. Many years ago you could get funding for an idea, a piece of data, or a novel platform. With little exaggeration, funding could be generally raised as long as there was promise and the ability to tell a story, or until the concept was fully disproven.

  • Building A Biotech Hub – Austin Style
    Building A Biotech Hub – Austin Style

    There is a serious push to make Texas the “Third Coast” of biotech and Austin, in particular, a new hub for the industry.

  • Academia Finds New Ways To Partner With Pharma
    Academia Finds New Ways To Partner With Pharma

    For the past decade, academia and industry have become increasingly collaborative, finding ways to shed cautious attitudes and successfully advance programs together. Now, academia is taking a proactive, strategic approach that promises to further catalyze industry relationships and increase opportunities for commercialization and monetization of the most promising technologies.

  • Why More Incentives Are Needed To Tackle Antibiotic Resistance
    Why More Incentives Are Needed To Tackle Antibiotic Resistance

    Antibiotic resistance is a real and immediate threat that is beginning to garner the global attention it needs and deserves. During a meeting of the United Nations in September 2016, the entire General Assembly — 193 nations — reaffirmed its commitment to developing national action plans on combatting antibiotic resistance.

  • What JPM 2017 Revealed To Me
    What JPM 2017 Revealed To Me

    As I walked into a breakout session on at JPM, I couldn’t help but overhear people discussing the latest negative news to hit the biopharma industry.

  • What Gets Funded, What Dies Before It Gets To Pharma R&D
    What Gets Funded, What Dies Before It Gets To Pharma R&D

    Lots of people in our industry are wondering how to simultaneously bring value to patients and the organization. It’s a reasonable aspiration, but is it possible?

  • How To Navigate Pharma Collaboration And Licensing Agreements
    How To Navigate Pharma Collaboration And Licensing Agreements

    Collaboration and licensing agreements are an indispensable business strategy for both pharmaceutical companies with commercial capabilities and biotech companies developing novel therapeutics.

  • Orphan Drug Incentives & Innovations On The Rise
    Orphan Drug Incentives & Innovations On The Rise

    The FDA and EMA are giving unprecedented support to addressing the rare disease need, aiming efforts largely at the biotech and specialty pharma companies that are at the forefront of orphan drug development.

  • Are You Ready To Fund Your Life Sciences Startup?
    Are You Ready To Fund Your Life Sciences Startup?

    If you have an idea for a life sciences product geared toward meeting an unmet medical need, you have probably given a lot of thought as to what makes it special, as well as why insurance companies should be willing to pay for it. But no matter how differentiated or breakthrough your innovation might be, if you haven’t considered how to finance your vision, it likely won’t ever see the light of day.

More Finance/Funding Articles